Enteliqo

My company Enteliqo, is developing the world’s first medical device to help Emergency Physicians and GPs improve the accuracy and speed in the diagnosis of dyspnoea (the medical term for shortness of breath). We do this, using advances in medical photonics and artificial intelligence.

Dyspnoea is caused by an underlying heart or lung condition and is seen in up to 30% of all patients presenting to hospital emergency departments. It has a high mortality and thus early detection of the underlying causes is life-saving.

Team - I have a co founder (Dr Johan Verjans) who is a Cardiologist trained at Harvard and has strong experience in commercialising medical technology. He is also the Director of the Australian Institute of Machine Learning.
I myself have as medical background with an MBA from the University of Melbourne. I have over 25 years of experience in leading strategy and operations in multinational pharmaceutical and medical device companies such as Abbott and 3M.

We also have an experienced advisory board which adds significant experience in strategy, finance, med tech commercialisation and marketing.

Finally we have an eco system of partners to ensure successful end to end commercialisation - e.g. consultants in lean methodology, project management, clinical trials, regulatory affairs, health economics, intellectual property and digital marketing.

Product - We have the prototype ready. The product is at a technology
We have had interests from 18 leading hospitals across 6 countries to participate in clinical trials. We have also had interests from 3 multinational pharmaceutical companies for the concept.

The Target Customers -
Hospitals - Emergency Physicians, Cardiologists, Neonatal Intensive Care Physicians
Hospital Payers
GPs
Ambulance Services

We are targeting 12 countries for selling our product and there are 45,000 hospitals and 220,000 GP clinics in these countries.

The total global market for the diagnosis of Dyspnoea is US$ 6.8 Bn. The addressable market size if US$ 1.4 Bn

Dyspnoea (the medical term for shortness of breath, is very common medical condition & usually due to an underlying heart or lung disease. It occurs in up to 30% patients in emergency & 25% patients in ambulatory settings. It is associated with very high mortality rates – Thus the earliest possible start of right treatment is life saving and critical.

A rapid non-invasive tool that can identify the main causes of Dyspnoea could revolutionise healthcare provision and can be lifesaving for this patient group.

The current process for diagnosis of Dyspnoea takes hours to a few days. Our device helps clinicians go from the current subjective assessment that takes hours to days, to a more accurate and objective assessment in a matter of seconds and out of hospital which saves money for payers.

Our product Breathelisa is first of its kind in the world – an AI driven medical laser diagnostic device for molecular capture of breath, that detects patterns, not only peaks in Dyspnoea. For GPs, Emergency Physicians & Ambulance Services, early diagnosis of shortness of breath has high clinical impact on treatment outcome. Breathelisa is disruptive in the point of care for GPs and Ambulance Services, who now go from the current subjective assessment of dyspnoea to a highly accurate and objective assessment of the disease.

Breathelisa produces extremely accurate, rapid & life-saving diagnosis with very low-risk for the patient. Most importantly, it helps keep patients out of hospital, which saves money for hospital payers. The Breathelisa platform has much wider applications into cancer detection, cardiac and respiratory disease, and microbiome footprint characterisation. Thus, Breathelisa has a global first mover advantage with true clinical & financial ROI.

There are no direct competitors.
Indirect competitors are company's such as GE Healthcare and Siemens that make diagnostic imaging equipment (MRIs etc) and company's like Beckman Coultar that make the capital equipment for blood biomarker exams and related reagents

Speed, Accuracy & Cost Effectiveness Via Out of Hospital Diagnosis.

Breathelisa is first of its kind in the world – an AI driven medical laser diagnostic device for molecular capture of breath, that detects patterns, not only peaks in Dyspnoea.

In the future, the Breathelisa platform has much wider applications into cancer detection, cardiac and respiratory disease, and microbiome footprint characterisation.

Thus, Breathelisa has a global first mover advantage with true clinical & financial ROI.

The Revenue Model
Perpetual License With Sell Price of $15,000 per unit + $2,475 per annum for ongoing maintenance and software upgrades.

Cost per unit = $3,100

The Target Customers -
Hospitals - Emergency Physicians, Cardiologists, Neonatal Intensive Care Physicians
Hospital Payers
GPs
Ambulance Services

Customer Relationships Driven By - Acquisitions, KOL Advocacy, Communities and Co Creation.

Unique Value To Customers
Breathelisa is first of its kind in the world – an AI driven medical laser diagnostic device for molecular capture of breath, that detects patterns, not only peaks in Dyspnoea. For GPs, Emergency Physicians & Ambulance Services, early diagnosis of shortness of breath has high clinical impact on treatment outcome. Breathelisa is disruptive in the point of care for GPs and Ambulance Services, who now go from the current subjective assessment of dyspnoea to a highly accurate and objective assessment of the disease.

Breathelisa produces extremely accurate, rapid & life-saving diagnosis with very low-risk for the patient. Most importantly, it helps keep patients out of hospital, which saves money for hospital payers. The Breathelisa platform has much wider applications into cancer detection, cardiac and respiratory disease, and microbiome footprint characterisation. Thus, Breathelisa has a global first mover advantage with true clinical & financial ROI.

The Revenue Model
Perpetual License With Sell Price of $15,000 per unit + $2,475 per annum for ongoing maintenance and software upgrades.

Cost per unit = $3,100

Sales In Year 1 Across 12 targeted Countries = 16,000 Units

Clinical Trials, Health Economic and Outcome Studies in 9 Countries
Regulatory Approvals - Europe, USA, Canada, Australia, New Zealand, Japan, Singapore, Vietnam, India
Price Reimbursements - Europe, USA, Canada, Australia, New Zealand, Japan, Singapore, Vietnam, India
Using Consulting Help For Strategic Exit or an IPO

35% Equity For US$11 Million investment

The major risk could come from the results from the clinical trials and health economic and outcome studies (versus the competition) not being favourable OR for some reason we do not get price reimbursements

I am participating in the incubator programs by AI Australia and the University of New South Wales Founders 10X Health programs. These will be completed in the next 12 weeks.

I have completed the BRIGHT and Digital Health Masterclass by AndHealth

The Global Marketing Excellence Award at 3M
Leadership Excellence Award at Cardinal Health

We are using the services of Baxter Patetnt Attorneys to file a PCT application for patent protection in multiple countries